

RESEARCH HIGHLIGHT Fibroblasts fuel intestinal tumorigenesis

Dingzhi Wang¹ and Raymond N. DuBois¹

Cell Research (2020) 30:635-636; https://doi.org/10.1038/s41422-020-0340-7

Intestinal stromal cells play key roles in the regulation of intestinal stem cell biology, injury-induced intestinal epithelial regeneration, and tumorigenesis. Roulis and colleagues present evidence indicating that PGE₂ secreted from PTGS2expressing fibroblasts induces expansion of Sca-1⁺ reserve stem-like cells and accelerates intestinal adenoma formation via an EP4-YAP1 pathway.

Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer deaths in the United States. Epidemiologic and experimental evidence strongly implicates chronic inflammation as a risk factor for multiple types of cancers, including CRC. Moreover, epidemiologic and clinical evidence that nonsteroidal anti-inflammatory drugs, including selective inhibitors of cyclooxygenase-2 (COX-2, also known as prostaglandin-endoperoxide synthases 2, PTGS2), suppress CRC formation and growth supports the hypothesis that COX-2 promotes CRC progression. COX enzymes convert arachidonic acid into prostanoids, including prostaglandins (PGs) such as PGE₂, PGD₂, PGF₂ α , PGI₂ and thromboxane A₂ (TxA₂) via specific PG synthases. Among prostanoids, PGE₂ is clearly the most abundant in human CRC and only PGE₂ and PGI₂ levels are elevated in human CRC specimens as compared to matched normal tissues.¹ Moreover, multiple lines of in vivo evidence demonstrate that only PGE₂ accelerates intestinal tumor formation and growth.¹ The roles of other PGs in CRC remain unclear and controversial.¹ PGE₂ exerts its effects by binding to EP receptors (EP1, EP2, EP3, and EP4) that belong to the family of G protein-coupled receptors. Similarly, animal studies demonstrate that PGE₂ promotes intestinal tumorigenesis via EP2 and EP4, but not EP3.¹ The role of EP1 in CRC remains unclear.¹

Although COX-2 is predominantly expressed in stromal cells such as macrophages, (myo)fibroblasts, and endothelial cells in human and rodent intestinal tumors, it was unclear which COX-2expressing cells contribute to CRC. A recent study showed that macrophage-specific overexpression of COX-2 promoted colon tumor burden in Apc^{Min/+} mice, a mouse model of CRC.² In a recent Nature paper, Roulis et al. reported for the first time that fibroblast-specific deletion of Cox-2 attenuated intestinal tumor formation but did not affect tumor size in two mouse models of CRC, Apc^{Min/+} mice and azoxymethane-treated mice.³ Moreover, they confirmed that fibroblast-specific overexpression of Cox-2 accelerated tumor formation in $Apc^{Min/+}$ mice. Their results demonstrate that COX-2-expressing fibroblasts contribute to CRC initiation. In addition, they found that intestinal fibroblasts are a predominant source of COX-2 in the intestine under normal physiological conditions. It is unclear whether COX-2 is also mainly expressed in intestinal tumor-associated fibroblasts.

Intestinal stem cells (ISCs) are responsible for homeostatic epithelial renewal and injury-induced intestinal epithelial regeneration. Active Lgr5⁺ ISCs are responsible for homeostatic intestinal epithelial renewal, whereas surviving Lgr5⁺ ISCs, reserve ISCs such as Bmi1⁺ cells, and other mature cells are responsible for intestinal epithelial regeneration during injury and repair.⁴ Understanding how the ISC niche is regulated during injury and repair may provide new therapeutic approaches for human intestinal disorders. Although the stromal compartment plays a key role in the regulation of ISC niches, it is not clear which types of stromal cells produce different juxtracrine factors that are required for maintenance of ISC niches. Virshup's group has identified intestinal myofibroblasts that produce Wnts and RSPO3, involved in the regulation of ISCs in vivo.⁵ The results reported in this recent Nature paper showed for the first time that PGE₂ secreted from fibroblasts induced expansion of SCA-1⁺ reserve intestinal stemlike cells via EP4 receptor signaling in a 3D organotypic co-culture model of primary intestinal fibroblasts and fresh crypts (Fig. 1).³ However, further studies are necessary to confirm whether these SCA-1⁺ cells are reserve ISCs.

PGE₂ has been shown to promote colonic epithelial regeneration via Yap1 in a mouse model of colitis.⁶ Similarly, PGE₂ secreted from mesenchymal stem cells (MSCs) attenuated acute liver failure by induction of hepatocyte proliferation and survival via YAP in a mouse model of acute liver failure.⁷ Given that ISCs are responsible for injury-induced intestinal regeneration, it is conceivable that PGE₂ promotes regeneration of intestinal epithelium via induction of ISC expansion following injury. Indeed, Roulis et al. showed that PGE₂ induced expansion of SCA-1⁺ reserve intestinal stem-like cells via an EP4-Yap1 pathway in their 3D organotypic co-culture model (Fig. 1).³ It would be very interesting to determine whether PGE₂ secreted from fibroblasts promotes intestinal epithelial regeneration by induction of reserve ISC expansion via an EP4-Yap1 pathway in mouse models of inflammatory bowel disease.

Cancer stem cells (CSCs) or tumor-initiating cells (mutant stem cells) are thought to be responsible for tumor initiation, growth, metastatic spread, relapse, and recurrence. How CSCs are formed, maintained, and expanded are not fully understood. Similar to ISCs, stromal cells also contribute to CSC formation and expansion via production of certain factors. For example, PGE₂ secreted from MSCs induced colonic CSC formation in vitro.⁸ PGE₂ secreted from myeloid-derived suppressive cells might also induce cervical CSC formation and expansion in vitro.⁹ Moreover, PGE₂ has been shown to induce colonic CSC expansion by activating NF-κB via EP4–PI3K and EP4–MAPK signaling and promote liver metastases in an orthotopic mouse model of metastatic CRC.¹⁰ In CRC cell

Published online: 3 June 2020

¹Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 601 Clinical Science Building, 96 Jonathan Lucas Street, Suite 601, Charleston, SC 29425, USA

Correspondence: Raymond N. DuBois (duboisrn@musc.edu)




Fig. 1 The role of COX-2-expressing fibroblasts in expansion of SCA-1⁺ intestinal stem-like cells and intestinal adenoma formation. COX-2 converts arachidonic acid into PGs, including PGE₂ in intestinal fibroblasts. PGE₂ induces expansion of SCA-1⁺ reserve intestinal stem-like cells via an EP4-Yap1 pathway. PGE₂ also accelerates intestinal adenoma formation accompanied by SCA-1⁺ cell expansion via an EP4-Yap1 pathway.

lines, PGE₂ induced YAP1 expression and transcriptional activity, which resulted in induction of both COX-2 and EP4 gene transcription.⁶ This positive signaling loop of PGE₂-YAP1 induced cell proliferation as well.⁶ Roulis et al. presented data showing that epithelial-specific deletion of *Yap1* or *Ep4* in *Apc^{Min/+}* mice resulted in reduction of Yap1 target gene expression, Sca-1⁺ cell expansion, and tumor formation when compared to control mice. Since Sca-1 is one of the CSC markers and also one of Yap-1 target genes, their results suggest that PGE₂ promotes intestinal adenoma formation by induction of mutant ISC expansion via the EP4-Yap1 pathway in a spontaneous murine model of CRC (Fig. 1). Further investigation is needed to provide direct evidence demonstrating that PGE₂ secreted from fibroblasts accelerates intestinal adenoma formation by induction of mutant ISC expansion via the EP4-Yap1 pathway.

Collectively, these findings not only reveal a novel mechanism underlying contribution of fibroblast-derived PGE_2 to expansion of SCA-1⁺ reserve intestinal stem-like cells and intestinal adenoma formation (Fig. 1), but also support the rationale for developing

EP4 antagonists as new anti-tumor agents in CRC treatment. Frankly, targeting colonic CSCs may present a novel therapeutic approach for CRC patients.

REFERENCES

- 1. Wang, D. & DuBois, R. N. J. Clin. Invest. 128, 2732-2742 (2018).
- 2. Hull, M. A. et al. Sci. Rep. 7, 6074 (2017).
- 3. Roulis, M. et al. Nature 580, 524-529 (2020).
- Santos, A. J. M., Lo, Y. H., Mah, A. T. & Kuo, C. J. Trends Cell Biol. 28, 1062–1078 (2018).
- 5. Greicius, G. et al. Proc. Natl. Acad. Sci. USA 115, E3173-E3181 (2018).
- 6. Kim, H. B. et al. Gastroenterology 152, 616-630 (2017).
- 7. Liu, Y. et al. FASEB J. 33, 2514–2525 (2019).
- Li, H. J., Reinhardt, F., Herschman, H. R. & Weinberg, R. A. Cancer Discov. 2, 840–855 (2012).
- 9. Kuroda, H. et al. Oncotarget 9, 36317-36330 (2018).
- 10. Wang, D., Fu, L., Sun, H., Guo, L. & DuBois, R. N. *Gastroenterology* **149**, 1884–1895 (2015).